Disease progression of spinocerebellar ataxia types 1, 2, 3 and 6 before and after ataxia onset

Author:

Jacobi Heike1ORCID,Schaprian Tamara2,Schmitz‐Hübsch Tanja3ORCID,Schmid Matthias24,Klockgether Thomas25,

Affiliation:

1. Department of Neurology University Hospital Heidelberg Heidelberg Germany

2. German Center for Neurodegenerative Diseases (DZNE) Bonn Germany

3. Experimental and Clinical Research Center, a cooperation of Max‐Delbrueck Center for Molecular Medicine and Charité – Univeristätsmedizin Berlin Berlin Germany

4. Department of Medical Biometry, Informatics and Epidemiology, Medical Faculty University of Bonn Bonn Germany

5. Department of Neurology University Hospital of Bonn Bonn Germany

Abstract

AbstractObjectiveOur aim was to study the evolution of ataxia and neurological symptoms before and after ataxia onset in the most common spinocerebellar ataxias (SCAs), SCA1, SCA2, SCA3 and SCA6. We therefore jointly analysed the data of the EUROSCA and RISCA studies, which recruited ataxic and non‐ataxic mutation carriers.MethodsWe used mixed effect models to analyse the evolution of Scale for the Rating and Assessment of Ataxia (SARA) scores, SCA Functional Index (SCAFI) and Inventory of Non‐Ataxia Signs (INAS) counts. We applied multivariable modelling to identify factors associated with SARA progression. In the time interval 5 years prior to and after ataxia onset, we calculated sensitivity to change ratios (SCS) of SARA, SCAFI and INAS.Results2740 visits of 677 participants were analysed. All measures showed non‐linear progression that was best fitted by linear mixed models with linear, quadratic and cubic time effects. R2 values indicating quality of the fit ranged from 0.70 to 0.97. CAG repeat was associated with faster progression in SCA1, SCA2 and SCA3, but not SCA6. 5 years prior to and after ataxia onset, SARA had the highest SCS of all measures with a mean of 1.21 (95% CI: 1.20, 1.21) in SCA1, 0.94 (0.93, 0.94) in SCA2 and 1.23 (1.22, 1.23) in SCA3.InterpretationOur data have important implications for the understanding of disease progression in SCA1, SCA2, SCA3 and SCA6 across the lifespan. Furthermore, our study provides information for the design of interventional trials, especially in pre‐ataxic mutation carriers close to ataxia onset and patients in early disease stages.

Publisher

Wiley

Subject

Neurology (clinical),General Neuroscience

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3